The Association Between Abdominal Aortic Aneurysms With Cardiovascular and Noncardiovascular Diseases

Paraskevas, Kosmas I.; Veith, Frank J.; Mikhailidis, Dimitri P.

doi:10.1177/0003319718785790

Angiology

2018

DOI: 10.1177/0003319718785790

|View full text |Cite

The Association Between Abdominal Aortic Aneurysms With Cardiovascular and Noncardiovascular Diseases

Kosmas I. Paraskevas

Frank J. Veith

Dimitri P. Mikhailidis

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...

Citation Types

Supporting

Mentioning

Contrasting

Year Published

2018

2021

Publication Types

Select...

Article5

Relationship

Self Cite1

Independent4

Authors

Journals

Cited by 5 publications

(1 citation statement)

References 41 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…9 Patients with AAAs have a high incidence of cardiovascular (CV) and non-CV diseases (eg, chronic obstructive pulmonary disease, chronic kidney disease, cancer, etc). 10 Up to 80% of AAA patients die not of a ruptured AAA but from other diseases (eg, cancer, myocardial infarction, or stroke). 11 Similarly, Hultgren et al reported that 82.9% of their AAA patients died from a non-AAA-related cause.…”

mentioning

confidence: 99%

Debating the Usefulness of Abdominal Aortic Aneurysm Screening Programs: A Never-Ending Story

Paraskevas¹,

Zeebregts

Veith

2020

Angiology

Self Cite

View full text Add to dashboard Cite

mentioning

confidence: 99%

Debating the Usefulness of Abdominal Aortic Aneurysm Screening Programs: A Never-Ending Story

Paraskevas¹,

Zeebregts

Veith

2020

Angiology

Self Cite

View full text Add to dashboard Cite

Cardiovascular safety of oncologic agents: a double-edged sword even in the era of targeted therapies – Part 2

Manolis

Manolis²,

Mikhailidis

et al. 2018

Expert Opinion on Drug Safety

View full text Add to dashboard Cite

Patients with cancer are subject to the cardiotoxic effects of cancer therapy. Improved cancer treatments lead to more cancer-survivors, who though are exposed to various forms of cardiovascular (CV) disease (CVD) as they age. Aging patients are at increased risk of developing both malignancy and CVD or they may have survived some form of CVD as a result of effective CV treatments. Furthermore, patients with CVD may develop cancer and require treatment (and vice versa), all contributing to increased morbidity and mortality. The prevalence of both malignancy and CVD will increase due to the trend toward a longer lifespan. Areas covered: In part 2 of this review, the discussion of the CV effects of specific oncology drugs is completed with inclusion of additional immunological agents, current hormonal and other agents. Early detection and monitoring of cardiotoxicity, use of biomarkers and other imaging and diagnostic methods and prevention and treatment options are also discussed. Expert opinion: As outlined in part 1 of this review, oncologists need to be aware of the CV adverse-effects of their treatments and make careful and expectant clinical decisions, especially in patients with preexisting CVD or CV risk factors. Similarly, cardiologists should consider a detailed previous history of treatment for malignant disease, including prior chemotherapy exposure, dose(s) received, and/or combined modality therapy with chest radiotherapy. Both specialists should collaborate in order to minimize the impact of these two ubiquitous diseases (cancer and CVD) and mitigate the adverse effects of treatment modalities.

show abstract

Multifocal arterial disease: clinical implications and management

Paraskevas

Geroulakos

Veith

et al. 2020

Current Opinion in Cardiology

View full text Add to dashboard Cite

Purpose of review Vascular disease often affects more than one territory. Atherosclerosis is a global disease affecting multiple organs/systems. Cardiovascular risk factors are associated with an increased risk for the development of arterial disease in all vascular beds but differ in their individual impacts for each vascular bed. We discuss the various options to identify and manage multifocal arterial disease. Recent findings Coronary artery disease may coexist with carotid artery stenosis, abdominal aortic aneurysms, and/or peripheral artery disease (PAD). Atherosclerotic renal artery stenosis and renal function impairment may complicate PAD. Recent studies have confirmed that patients with multivascular bed disease have higher risk than patients with monovascular disease. In addition to the specific surgical/endovascular therapeutic options available, aggressive medical treatment and vascular disease prevention strategies should be rigorously implemented to best manage the overall atherosclerotic burden. Summary A holistic approach is essential to reduce the cardiovascular morbidity and mortality rates of vascular patients. Preventive measures should complement surgical/endovascular procedures so as to improve outcomes.

show abstract

scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.

Contact Info

customersupport@researchsolutions.com

10624 S. Eastern Ave., Ste. A-614

Henderson, NV 89052, USA

Blog Terms and Conditions API Terms Privacy Policy Contact Cookie Preferences Do Not Sell or Share My Personal Information

Made with 💙 for researchers

Part of the Research Solutions Family.

The Association Between Abdominal Aortic Aneurysms With Cardiovascular and Noncardiovascular Diseases

Cited by 5 publications

References 41 publications

Debating the Usefulness of Abdominal Aortic Aneurysm Screening Programs: A Never-Ending Story

Debating the Usefulness of Abdominal Aortic Aneurysm Screening Programs: A Never-Ending Story

Cardiovascular safety of oncologic agents: a double-edged sword even in the era of targeted therapies – Part 2

Multifocal arterial disease: clinical implications and management

Contact Info

Product

Resources

About